ClinicalTrials.gg
CompletedNCT01213368Updated Oct 16, 2013

Dose Ranging Study of Dronedarone for the Control of Ventricular Rate in Japanese Patients With Permanent Atrial Fibrillation

A Phase 2 interventional study of DRONEDARONE (SR33589) and placebo in Atrial Fibrillation, sponsored by Sanofi. Completed at 25 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-10-16.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.

Enrollment
12th of 26
181 · median 164
Started
2010
with 8 others
Phase 2
2 of 26
none open now
Registered
15th of 26
by date
Lead sponsor
13 of 26
Sanofi

Among the 26 studies testing dronedarone in Atrial Fibrillation, this one is the 12th largest by enrollment, is one of 9 that started in 2010, is one of 2 in phase 2, and was the 15th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dronedarone

Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing dronedarone in Atrial Fibrillation, or all of them as a file.
02

Study summary

Primary Objective:

  • To assess the efficacy of dronedarone versus placebo for the control of ventricular rate in patients with permanent Atrial Fibrillation (AF).

Secondary Objective:

  • To assess the safety and tolerability of dronedarone after repeated oral doses of 300 mg, 400 mg, or 600 mg twice daily in the selected population.
  • To document SR33589 and SR35021 trough plasma levels at steady state.
Read the detailed description

The study period per patient is approximatively 1 month broken down as follows:

  • Screening period up to 7 days,
  • Treatment period of 14 days,
  • Follow-up period of 10 days.
03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of aged 20 years or more.
  • Permanent Atrial Fibrillation [AF] (defined as duration of AF > 6 months) for which cardioversion is not considered and with resting ventricular heart rate ≥ 80 bpm at screening.

Exclusion criteria

Exclusion criteria:

  • Unstable angina pectoris.
  • History of torsades de pointes.
  • Prolonged corrected interval (≥ 500 ms).
  • Third degree atrioventricular block (AVB) on the screening while in AF or, documentation on previous ECGs while in sinus rhythm of PR-interval > 0.28 sec or high degree AVB (2nd degree or higher) or, significant sinus node disease (documented pause ≥ 3 sec) - without a permanent pacemaker implanted.
  • Congestive Heart Failure (CHF) of classification (NYHA) class IV or recent (within 1 month prior to randomization) unstable NYHA class III.
  • Treatment with other class I or III anti-arrhythmic drugs.
  • Patients treated with amiodarone during the 4 weeks preceding randomization.
  • haematologic, hepatic, gastro-intestinal, renal, pulmonary, endocrinologic (in particular thyroid) or psychiatric disease.
  • Hypokalemia and hypomagnesemia must be corrected before randomization.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    dronedarone 300 mg

    Dronedarone, 100mg + 200mg tablets twice daily, administered with food.

    Drug: DRONEDARONE (SR33589)

  • Experimental
    dronedarone 400 mg

    Dronedarone, 400mg tablets twice daily, administered with food.

    Drug: DRONEDARONE (SR33589)

  • Experimental
    dronedarone 600 mg

    Dronedarone, 400mg + 200mg tablets twice daily, administered with food.

    Drug: DRONEDARONE (SR33589)

  • Placebo comparator
    placebo

    Matching placebo tablets twice daily, administered with food.

    Drug: placebo

Interventions

  • Pharmaceutical form: tablets Route of administration: oral

  • Drugplacebo

    Pharmaceutical form: tablets Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Change from baseline in mean ventricular rate measured by 24-hour Holter Electrocardiogram (ECG)

    Time frame: Day 14

Secondary outcomes

  1. Number of patients with adverse events

    Time frame: up to 10 days after last drug intake

  2. Plasma trough concentrations for SR33589

    Time frame: Day 14

  3. Plasma trough concentrations for SR35021

    Time frame: Day 14

07

Study locations

25 sites
  • Investigational Site Number 392022
    Hiroshima-Shi, Japan
  • Investigational Site Number 392018
    Kagoshima-Shi, Japan
  • Investigational Site Number 392005
    Kasama-Shi, Japan
  • Investigational Site Number 392014
    Kawanishi-Shi, Japan
  • Investigational Site Number 392008
    Kawasaki-Shi, Japan
  • Investigational Site Number 392007
    Kisarazu-Shi, Japan
  • Investigational Site Number 392012
    Kobe-Shi, Japan
  • Investigational Site Number 392013
    Kobe-Shi, Japan
  • Investigational Site Number 392003
    Koriyama-Shi, Japan
  • Investigational Site Number 392017
    Kurume-Shi, Japan
  • Investigational Site Number 392023
    Miyazaki-Shi, Japan
  • Investigational Site Number 392009
    Nagano-Shi, Japan
  • Investigational Site Number 392019
    Nagasaki-Shi, Japan
  • Investigational Site Number 392010
    Osaka-Shi, Japan
  • Investigational Site Number 392021
    Sapporo-Shi, Japan
  • Investigational Site Number 392025
    Sapporo-Shi, Japan
  • Investigational Site Number 392002
    Sendai-Shi, Japan
  • Investigational Site Number 392004
    Shirakawa-Shi, Japan
  • Investigational Site Number 392016
    Shunan-Shi, Japan
  • Investigational Site Number 392020
    Suwa-Shi, Japan
  • Investigational Site Number 392006
    Takasaki-Shi, Japan
  • Investigational Site Number 392001
    Tomakomai-Shi, Japan
  • Investigational Site Number 392024
    Toshima-Ku, Japan
  • Investigational Site Number 392015
    Ube-Shi, Japan
  • Investigational Site Number 392011
    Yao-Shi, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2010
First posted
Oct 4, 2010
Start
Sep 2010
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Last update
Oct 16, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01213368
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 4, 2010
Start date
Sep 2010
Primary completion
Apr 2011
Completion
Apr 2011
Last update
Oct 16, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronedarone

Start the discussion